Top 3 oversold ASX stocks to buy in June

The following are three of the top oversold ASX shares to buy in June 2026 which are trading at attractive valuations despite strong underlying business performance and compelling long-term growth prospects.

Cochlear Limited (ASX: COH) 

Cochlear Limited has declined 61.5% over the past twelve months despite its position as the global leader in implantable hearing solutions which has made it one of the oversold ASX shares to buy in June 2026.

The company in HY26 reported sales revenue of $1.176 billion which was 1% higher than the previous year while underlying net profit declined 9% to $194.8 million mainly because the rollout of the new Nucleus Nexa System progressed more slowly than expected although net cash remained strong at $173 million.

Management lowered FY26 underlying profit guidance to between $290 million and $330 million due to softer demand in developed markets and uncertainty in the Middle East.
Several recent developments have been positive including strong uptake of the Nucleus Nexa System and a broad R&D pipeline that features drug-eluting implants and totally implantable cochlear implants.

The company is confident in its long-term strategy and has increased investment in the adults and seniors hearing-loss market. A significant opportunity exists because more than 60 million people worldwide experience severe or higher hearing loss while fewer than 5% of eligible patients have received an implant which provides a substantial runway for future expansion.

CSL Limited (ASX: CSL) 

CSL Limited is a solid oversold ASX share to buy in June 2026 as the healthcare leader is down nearly 60% over the past twelve months while current market capitalisation is $47.3 billion.
The company recently updated its FY26 guidance and now expects revenue of approximately US$15.2 billion along with NPATA of around US$3.1 billion on a constant-currency basis.

A company-wide transformation program has also been accelerated with a target of US$500 million to US$550 million in annual savings by FY28 through operational simplification and supply-chain efficiencies etc.

Long-term growth prospects are supported by powerful structural drivers because only a fraction of immunoglobulin patients worldwide have been diagnosed and treated which leaves significant room for expansion across the company's core plasma business.

CSL is financially strong with a current annual unfranked dividend yield of 4.31% and a clearly defined strategy that is focused on its core operations while also investing in future growth opportunities.

Universal Store Holdings Limited (ASX: UNI) 

Universal Store Holdings Limited is one of the oversold ASX shares to buy in June 2026 as the youth fashion retailer's share price is down almost 21% over the past twelve months despite strong earnings growth and solid sales momentum across its key brands.

The company in H1 FY26 reported sales of $209.6 million which increased 14.2% year-on-year while underlying EBIT rose 23.2% to $43.6 million and underlying EPS increased 21.5% to 36.8 cents.

Gross margin improved by 150 basis points to 62.1% and the company ended the half with $38.4 million in cash and no borrowings which highlights one of the strongest balance sheets in the Australian retail sector.

Universal Store has expanded its store network, invested in technology and customer experience and benefited from a differentiated product offering which has supported premium pricing and disciplined inventory management.

The current market capitalisation is $475.67 million and has a fully franked dividend yield of 6.85% with a payout ratio of 71% and a strong track record across multiple retail brands.

(Source: Company Announcements)